Orthofix Medical (NASDAQ:OFIX) Price Target Cut to $56.00

Orthofix Medical (NASDAQ:OFIX) had its target price reduced by Sidoti from $70.00 to $56.00 in a note issued to investors on Tuesday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the medical device company’s stock. Sidoti’s price objective suggests a potential upside of 53.47% from the stock’s current price.

A number of other analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Orthofix Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 1st. ValuEngine raised shares of Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday. Cantor Fitzgerald reduced their target price on shares of Orthofix Medical from $48.00 to $42.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, BidaskClub raised shares of Orthofix Medical from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $52.33.

Shares of NASDAQ OFIX opened at $36.49 on Tuesday. The company has a current ratio of 3.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.06. Orthofix Medical has a 12 month low of $35.99 and a 12 month high of $61.86. The firm has a market capitalization of $699.32 million, a PE ratio of -24.01, a price-to-earnings-growth ratio of 3.50 and a beta of 0.46. The firm has a fifty day simple moving average of $44.69 and a two-hundred day simple moving average of $47.64.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, February 24th. The medical device company reported $0.51 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.51. Orthofix Medical had a negative net margin of 6.19% and a positive return on equity of 8.58%. The business had revenue of $121.49 million during the quarter, compared to analyst estimates of $122.90 million. On average, sell-side analysts predict that Orthofix Medical will post 1.05 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Marshall Wace North America L.P. purchased a new stake in Orthofix Medical during the 1st quarter valued at about $25,000. Point72 Hong Kong Ltd grew its position in Orthofix Medical by 246.0% during the 4th quarter. Point72 Hong Kong Ltd now owns 557 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 396 shares during the last quarter. NumerixS Investment Technologies Inc purchased a new stake in Orthofix Medical during the 4th quarter valued at about $37,000. Meeder Asset Management Inc. grew its position in Orthofix Medical by 461.7% during the 4th quarter. Meeder Asset Management Inc. now owns 3,758 shares of the medical device company’s stock valued at $173,000 after purchasing an additional 3,089 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Orthofix Medical during the 4th quarter valued at about $210,000. 95.27% of the stock is currently owned by hedge funds and other institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.

See Also: Green Investing

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.